Advertisement
Advertisement
U.S. markets close in 3 hours 16 minutes
Advertisement
Advertisement
Advertisement
Advertisement

POINT Biopharma Global Inc. (PNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.65-0.07 (-1.04%)
As of 12:42PM EST. Market open.
Advertisement

POINT Biopharma Global Inc.

4850 West 78th Street
Indianapolis, IN 46268
United States
647 812 2417
https://www.pointbiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Mr. Allan Charles SilberExec. Chairman677.8kN/A1950
Dr. Joe A. McCann Ph.D.CEO & Director740.31kN/A1978
Dr. Neil E. Fleshner FRCSC, M.D., M.PHChief Medical Officer & Director227.5kN/A1964
Ms. Jessica D. Jensen M.P.H., MPHExec. VP of Clinical Devel.541.59kN/A1981
Mr. Bill Demers B.B.A., F.C.A., FCPAChief Financial OfficerN/AN/A1958
Ms. Justyna Kelly M.Sc.Chief Operating OfficerN/AN/A1985
Ms. Donna Husack B.A.VP of HRN/AN/AN/A
Mr. Todd Hockemeyer B.E.Exec. VP of US Manufacturing OperationsN/AN/AN/A
Mr. Ari ShomairVP of Corp. Affairs & Chief of StaffN/AN/AN/A
Dr. Myra Rosario Herle Ph.D., R.Ph.Exec. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Corporate Governance

POINT Biopharma Global Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement